| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| venetoclax indication | 1.58 | 0.1 | 7587 | 86 | 21 |
| venetoclax | 1.06 | 0.3 | 7435 | 55 | 10 |
| indication | 0.28 | 0.7 | 7742 | 87 | 10 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| venetoclax indication | 1.21 | 0.2 | 8190 | 32 |
| venetoclax indication in aml | 1.59 | 0.3 | 3592 | 30 |
| venetoclax cll indication | 1.5 | 0.3 | 8911 | 37 |
| venetoclax resistance in aml | 1.99 | 0.6 | 5071 | 37 |
| venetoclax fda approval aml | 1.73 | 0.8 | 4066 | 14 |
| venetoclax in relapsed aml | 1.52 | 0.9 | 4558 | 33 |
| venetoclax aml phase 1 | 0.13 | 0.3 | 8611 | 44 |
| venetoclax mechanism of action aml | 0.6 | 1 | 4191 | 54 |
| venetoclax package insert aml | 0.76 | 0.6 | 7157 | 58 |
| venetoclax aml 14 days | 0.34 | 0.8 | 8713 | 49 |
| aza and venetoclax for aml | 0.8 | 0.5 | 3871 | 60 |
| venetoclax and vidaza for aml | 1.08 | 0.6 | 2389 | 44 |
| venetoclax azacitidine aml protocol | 1.38 | 0.1 | 2017 | 17 |
| venetoclax + azacitidine aml protocol pdf | 1.81 | 1 | 921 | 64 |
| venetoclax and azacitidine aml | 1.3 | 0.9 | 554 | 71 |
| duration of venetoclax aml | 1.14 | 0.3 | 8338 | 44 |
| venetoclax success rate aml | 0.02 | 0.7 | 3063 | 39 |
| venetoclax acute myeloid leukemia | 0.52 | 0.3 | 1417 | 3 |
| venetoclax ramp up aml | 0.06 | 1 | 6927 | 89 |
| venetoclax azacitidine relapsed aml | 0.53 | 0.7 | 932 | 54 |
| decitabine and venetoclax for aml | 0.03 | 1 | 4710 | 71 |
| venetoclax azacitidine aml eviq | 1.95 | 0.9 | 1052 | 76 |
